CompaniesGeneTx Biotherapeutics

GeneTx Biotherapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (12)
View all

Total Trials

12

As Lead Sponsor

12

As Collaborator

0

Total Enrollment

352

By Phase

PHASE2: 5PHASE1/PHASE2: 2PHASE1: 4

By Status

COMPLETED: 10UNKNOWN: 1TERMINATED: 1
Clinical Trials Pipeline12 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
Today
NCT00429312
NCT00625456
NCT00554372
NCT01387555
NCT01171651
NCT01380600
NCT01169584
NCT01394939
Hover over trial bars to see details

Recent Trials

NCT04090970Lead Sponsor
Briagen Observational Study
N/AUnknown
30 participants
Started: Aug 26, 2019 · Completed: May 31, 2020
NCT01636284Lead Sponsor
A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer
PHASE2Completed
16 participants
Started: Jun 30, 2012 · Completed: Jun 30, 2013
NCT01394939Lead Sponsor
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
PHASE1/PHASE2Completed
52 participants
Started: Jan 31, 2012 · Completed: Oct 31, 2015
NCT01329809Lead Sponsor
Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors
PHASE2Terminated
2 participants
Started: Oct 31, 2011 · Completed: Mar 31, 2013
NCT01169584Lead Sponsor
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
PHASE1Completed
6 participants
Started: Aug 31, 2010 · Completed: Nov 30, 2014
View all 12 trials →
Funding History (2)
D/A
Apr 3, 2019
Filing
D
Nov 2, 2018
Filing
Related Companies
Ultragenyx
acquired